MTBVAC

About Biofabri

Biofabri is a private, clinical-stage biotech company developing next-generation vaccines and immunotherapies. Its lead asset, MTBVAC, is a promising tuberculosis vaccine candidate that has progressed to Phase 2 clinical trials and aims to improve upon the century-old BCG vaccine. The company leverages a broad technology platform spanning classic, genetically engineered, subunit, and nucleic acid-based vaccines to address significant infectious diseases and oncology indications. As part of the Zendal Group, Biofabri benefits from integrated manufacturing and development capabilities within the larger organization.

About Biofabri

Biofabri is a private, clinical-stage biotech company developing next-generation vaccines and immunotherapies. Its lead asset, MTBVAC, is a promising tuberculosis vaccine candidate that has progressed to Phase 2 clinical trials and aims to improve upon the century-old BCG vaccine. The company leverages a broad technology platform spanning classic, genetically engineered, subunit, and nucleic acid-based vaccines to address significant infectious diseases and oncology indications. As part of the Zendal Group, Biofabri benefits from integrated manufacturing and development capabilities within the larger organization.

Therapeutic Areas